NOVEL SELECTIVE AGONISTS AND ANTAGONISTS CONFIRM NEUROKININ NK1 RECEPTORS IN GUINEA-PIG VAS-DEFERENS

被引:32
作者
HALL, JM
MORTON, IKM
机构
[1] Pharmacology Group, Div. of Biomedical Sciences, King's College London, London SW3 6LX, Manresa Road
关键词
D O I
10.1111/j.1476-5381.1991.tb12202.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 This study investigated the recognition characteristics of neurokinin receptors mediating potentiation of the contractile response to field stimulation in the guinea-pig vas deferens. 2 A predominant NK1 receptor population is strongly suggested by the relative activities of the common naturally-occurring tachykinin agonists, which fall within less than one order of magnitude. This conclusion is supported by the relative activities of the synthetic NK1 selective agonists substance P methyl ester, [Glp6,L-Pro9]-SP(6-11) and delta-aminovaleryl-[L-Pro9,N-MeLeu10]-SP(7-11) (GR73632) which were 0.78, 9.3 and 120 as active as substance P, respectively. Furthermore, the NK2 selective agonist [Lys3, Gly8,-R-gamma-lactam-Leu9]-NKA(3-10) (GR64349) was active only at the highest concentrations tested (> 10-mu-M), and the NK3 selective agonist, succ-[Asp6,N-MePhe8]-SP(6-11) (senktide) was essentially inactive (10 nM-32-mu-M). 3 [D-Arg1,D-Pro2,D-Trp7,9,Leu11]-SP(1-11) antagonized responses to neurokinin A, neurokinin B, physalaemin, eledoisin, [Glp6,D-Pro9]-SP(6-11), GR73632 and GR64349 (apparent pK(B)s 5.6-6.2), but was less potent in antagonizing responses to substance P, substance P methyl ester and [Glp6,L-Pro9]-SP(6-11) (apparent pK(B)s less-than-or-equal-to 5.0-5.0). 4 In contrast, the recently developed NK1-selective receptor antagonist [D-Pro9[Spiro-gamma- lactam]Leu10, Trp11]-SP(1-11) (GR71251) did not produce agonist-dependent pK(B) estimates. Schild plot analysis indicated a competitive interaction with a single receptor population where the antagonist had an estimated overall pK(B) of 7.58 +/- 0.13 for the four antagonists of differeing subtype selectivity tested (GR73632, GR64349, substance P methyl ester and neurokinin B). This estimate is similar to that we obtained for NK1-mediated (substance P methyl ester) contraction in the guinea-pig ileum preparation (pK(B) = 7.86 +/- 0.05). 5 Tachykinin action appears not to depend on release of a number of intermediary mediators including acetylcholine, histamine or cyclo-oxygenase products, nor to involve interaction with neuronal mechanisms including alpha-2-adrenoceptor feedback, noradrenergic Uptake-1 or opioid-release, since antagonism or inhibition of these mechanisms did not modify responses to tachykinins. 6 We conclude that tachykinin action in the field-stimulated guinea-pig vas deferens preparation is mediated through interaction with a predominant neurokinin NK1 receptor population and this preparation can therefore be used to study NK1 modulation of sympathetic neurotransmission.
引用
收藏
页码:511 / 517
页数:7
相关论文
共 39 条
  • [1] AN EXAMINATION OF THE PHARMACOLOGY OF 2 SUBSTANCE-P ANTAGONISTS AND THE EVIDENCE FOR TACHYKININ RECEPTOR SUBTYPES
    BAILEY, SJ
    FEATHERSTONE, RL
    JORDAN, CC
    MORTON, IKM
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1986, 87 (01) : 79 - 85
  • [2] EFFECTS OF TACHYKININS ON INOSITOL PHOSPHOLIPID HYDROLYSIS IN SLICES OF HAMSTER URINARY-BLADDER
    BRISTOW, DR
    CURTIS, NR
    SUMANCHAUHAN, N
    WATLING, KJ
    WILLIAMS, BJ
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1987, 90 (01) : 211 - 217
  • [3] CASCIERI MA, 1981, MOL PHARMACOL, V20, P457
  • [4] SELECTIVE AGONISTS FOR SUBSTANCE-P AND NEUROKININ RECEPTORS
    DRAPEAU, G
    DORLEANSJUSTE, P
    DION, S
    RHALEB, NE
    ROUISSI, NE
    REGOLI, D
    [J]. NEUROPEPTIDES, 1987, 10 (01) : 43 - 54
  • [5] MODULATION OF NEUROTRANSMISSION IN THE GUINEA-PIG VAS-DEFERENS BY CAPSAICIN - INVOLVEMENT OF CALCITONIN GENE-RELATED PEPTIDE AND SUBSTANCE-P
    ELLIS, JL
    BURNSTOCK, G
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1989, 98 (02) : 707 - 713
  • [6] FLETCHER A E, 1987, British Journal of Pharmacology, V90, p266P
  • [7] BIOLOGICAL EVALUATION OF SUBSTANCE-P ANTAGONISTS
    FOLKERS, K
    HAKANSON, R
    HORIG, J
    CHENG, XJ
    LEANDER, S
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1984, 83 (02) : 449 - 456
  • [8] HAGAN RM, 1990, BRIT J PHARMACOL, V99, pP62
  • [9] HAGAN RM, 1989, BRIT J PHARMACOL, V98, pP717
  • [10] HALL J M, 1987, British Journal of Pharmacology, V91, p475P